4.7 Article

A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation

Journal

BLOOD
Volume 137, Issue 7, Pages 983-993

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2020009342

Keywords

-

Categories

Funding

  1. Public Health ServiceGrant from the National Institutes of Health [5U24-CA076518]
  2. National Cancer Institute (NCI)
  3. National Heart, Lung and Blood Institute (NHLBI)
  4. National Institute of Allergy and Infectious Diseases (NIAID)
  5. Health Resources and Services Administration/Department Health and Human Services (HRSA/DHHS) [HHSH250201200016C]

Ask authors/readers for more resources

By analyzing a large cohort of AML and ALL patients, we developed and validated a DRI for children and adolescents that can be used to stratify patients based on disease risk and predict their survival rates.
A disease risk index (DRI) that was developed for adults with hematologic malignancy who were undergoing hematopoietic cell transplantation is also being used to stratify children and adolescents by disease risk. Therefore, to develop and validate a DRI that can be used to stratify those with AML and ALL by their disease risk, we analyzed 2569 patients aged <18 years with acute myeloid (AML; n = 1224) or lymphoblastic (ALL; n = 1345) leukemia who underwent hematopoietic cell transplantation. Training and validation subsets for each disease were generated randomly with 1:1 assignment to the subsets, and separate prognostic models were derived for each disease. For AML, 4 risk groups were identified based on age, cytogenetic risk, and disease status, including minimal residual disease status at transplantation. The 5-year leukemia-free survival for low (0 points), intermediate (2, 3, 5), high (7, 8), and very high (>8) risk groups was 78%, 53%, 40%, and 25%, respectively (P < .0001). For ALL, 3 risk groups were identified based on age and disease status, including minimal residual disease status at transplantation. The 5-year leukemia-free survival for low (0 points), intermediate (2-4), and high (>= 5) risk groups was 68%, 51%, and 33%, respectively (P < .0001). We confirmed that the risk groups could be applied to overall survival, with 5-year survival ranging from 80% to 33% and 73% to 42% for AML and ALL, respectively (P < .0001). This validated pediatric DRI, which includes age and residual disease status, can be used to facilitate prognostication and stratification of children with AML and ALL for allogeneic transplantation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available